Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 25, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	43,218	52,535	30,350	24,021	29,238	20,282
Market Cap Growth	21.32%	73.09%	26.35%	-17.84%	44.16%	34.32%
Enterprise Value	44,204	52,584	30,296	24,278	29,564	19,873
Last Close Price	332.85	397.65	235.31	191.41	237.65	169.58
PE Ratio	140.45	167.44	-	-	-	-
Forward PE	48.80	60.03	-	-	-	-
PS Ratio	11.89	14.15	13.50	13.14	28.18	24.02
PB Ratio	55.83	66.57	452.40	-108.87	-184.79	34.48
P/TBV Ratio	55.94	66.57	452.40	-	-	34.48
P/FCF Ratio	94.85	112.89	-	572.67	-	-
P/OCF Ratio	84.23	100.24	-	230.62	-	-
EV/Sales Ratio	11.90	14.16	13.48	13.28	28.50	23.54
EV/EBITDA Ratio	79.33	94.37	-	-	-	-
EV/EBIT Ratio	88.13	104.84	-	-	-	-
EV/FCF Ratio	94.98	112.99	-	578.81	-	-
Debt / Equity Ratio	3.76	3.76	40.89	-12.16	-16.51	3.72
Debt / EBITDA Ratio	4.70	4.70	-	-	-	-
Debt / FCF Ratio	6.38	6.38	-	63.96	-	-
Net Debt / Equity Ratio	0.08	0.08	0.73	-1.10	-2.65	-0.42
Net Debt / EBITDA Ratio	0.11	0.11	-0.41	-1.07	-0.57	0.38
Net Debt / FCF Ratio	0.13	0.13	-1.15	5.80	-0.68	0.35
Asset Turnover	0.81	0.81	0.56	0.50	0.29	0.24
Inventory Turnover	8.46	8.46	3.86	2.85	1.57	1.74
Quick Ratio	2.51	2.51	2.61	2.86	3.17	3.79
Current Ratio	2.76	2.76	2.78	3.08	3.51	4.04
Return on Equity (ROE)	73.28%	73.28%	-	-	-526.14%	-106.31%
Return on Assets (ROA)	6.81%	6.81%	-2.74%	-4.78%	-13.65%	-12.56%
Return on Invested Capital (ROIC)	86.03%	100.88%	-255.24%	-198.35%	-261.58%	-132.10%
Return on Capital Employed (ROCE)	14.30%	14.30%	-5.80%	-9.90%	-28.30%	-24.00%
Earnings Yield	0.71%	0.60%	-0.92%	-1.83%	-3.87%	-4.21%
FCF Yield	1.05%	0.89%	-0.14%	0.18%	-2.10%	-3.54%
Buyback Yield / Dilution	-5.51%	-5.51%	-2.20%	-2.64%	-2.73%	-3.01%

Updated Feb 12, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q